EMEA-002563-PIP02-19-M01

Key facts

Active substance
cenobamate
Therapeutic area
Neurology
Decision number
P/0300/2021
PIP number
EMEA-002563-PIP02-19-M01
Pharmaceutical form(s)
  • Tablet
  • Film-coated tablet
  • Age-appropriate oral liquid dosage form
  • Age-appropriate dosage form for parenteral use
Condition(s) / indication(s)
Treatment of epilepsy
Route(s) of administration
  • Oral use
  • Parenteral use
  • Gastric use
Contact for public enquiries
Arvelle Therapeutics Netherlands B.V.

E-mail: info@arvelletx.com
Tel.: +41 (44)7982178

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating